Menveo is novel because it both covers four (A,C,W-135,Y) of the five major meningococcal serogroups and is immunogenic and safe when given as a four-dose schedule starting at 2 months of age 8.

The vaccine, branded as Penmenvy, combines the immune response-generating components of two of the company's approved ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 10, 2025 /EINPresswire / -- How Has the Menveo Market Performed in Recent Years, and What Does Its Future Hold? The Menveo market has experienced ...